Neubase therapeutics, inc. (OHRP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10
OPERATING ACTIVITIES
Net loss

-4,378

-4,505

-23,784

344

-2,029

-1,488

-6,355

-545

-2,184

-4,151

-5,244

-3,900

-7,690

-6,975

-6,636

-7,699

-5,284

-6,145

-3,910

-3,345

-3,343

-4,598

-3,089

-2,050

-1,968

-2,021

-1,803

-1,338

-292

-2,218

67

-460

-1,412

350

-1,358

-3,137

-156

-448

Adjustments to reconcile net loss to net cash used in operating activities
Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock issued for services

-

-

-

-

-

-

0

0

9

135

34

150

193

440

517

521

578

137

128

153

325

28

-

0

0

0

55

214

0

0

309

0

0

0

0

0

0

10

Warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

8

98

129

248

700

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

16

167

458

62

52

58

98

24

0

0

Stock-based compensation

1,339

1,504

9,571

-1,333

1,254

293

73

73

101

629

37

410

279

566

578

610

1,407

316

677

632

1,907

362

954

266

706

146

302

340

51

52

52

48

292

11

11

11

11

11

Research and development expense - license acquired

0

0

-

-

0

1,046

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-69

694

-

-

38

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

49

149

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

2

2

2

2

4

9

15

15

16

16

16

15

12

3

17

7

6

5

2

2

6

2

2

2

2

2

2

2

1

1

1

1

Amortization of intangible assets

-

-

-

-

-

-

279

276

275

282

282

279

276

282

282

279

279

282

282

279

278

297

299

110

19

19

19

19

19

19

19

19

19

19

-

-

19

19

Gain on settlement of liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Loss on disposal of fixed asset

0

-3

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-171

104

-1,305

2,557

486

-20

-3,786

683

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

21

-

-

-

-

Gain on sale of asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

70

0

Loss on derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,403

-

-

-

826

-

-

11

97

Equity in losses on equity method investment

-92

-24

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-5

-30

-41

-26

-10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash amortization on convertible notes

0

0

-

-

32

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on convertible notes

0

0

-

-

11

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Other prepaid expenses and current assets

-301

86

503

-119

2

-0

-145

-209

178

-134

-213

-133

-62

-247

387

-224

-1,537

1,439

-386

-40

-25

445

-55

-47

23

-25

-166

-60

-16

7

-267

26

93

41

79

19

-32

16

Long-term prepaid insurance

-48

-48

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

297

-110

-

-

440

-21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

502

-162

-

-

10

140

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other receivables and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

368

0

0

-184

-269

0

-0

150

Accounts payable and accrued expenses

-

-

-

-

-

118

2,402

-737

-3,532

-1,229

-608

-1,124

2,894

-507

766

1,758

38

948

-244

557

127

890

58

-427

470

-165

254

-102

109

-95

8

-21

-3

37

25

-4

12

-21

Net cash used in operating activities

-1,858

-2,441

-596

-1,989

-244

-14

-596

-1,181

-3,518

-4,195

-5,274

-4,117

-3,967

-5,930

-5,032

-4,184

-3,442

-3,326

-2,209

-1,677

-4,067

-2,738

-1,577

-1,946

-542

-1,292

-924

-727

-376

-661

-519

-424

-585

-224

-408

-229

-203

-163

Cash flows from investing activities
Purchase of laboratory and office equipment

93

68

451

-27

31

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

33

0

0

0

0

Payment of transaction costs for license acquired

0

0

-

-

0

43

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

0

0

0

4

1

1

1

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property, equipment and intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

70

0

Cash paid for license acquired

0

0

-

-

0

54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Net cash used in investing activities

-93

-68

-681

125

-31

-97

-

-

-

-

5

88

0

-4

-1

-1

-1

-10

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-33

0

0

70

0

Cash flows from financing activities
Principal payment of financed insurance

49

73

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in pre-acquisition financing, net of issuance costs

-

-

-

-

-

-

-

-

-

-

43

12,690

0

6,846

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

50

1,050

0

0

455

595

Repurchase of common stock

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of preferred stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Proceeds from warrants exercised for cash

-

-

-

-

-

-

0

0

45

225

0

0

0

118

0

12

0

13

0

-0

77

3

0

60

0

200

27

5,036

76

111

1,803

1,098

0

0

0

0

0

0

Proceeds from related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Repayments of related party payables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Proceeds from short-term notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-74

26

48

0

0

0

0

0

Repayments of short-term notes payable

-

-

-

-

-

-

108

106

35

106

52

102

0

87

43

84

0

48

71

69

23

43

65

85

0

14

28

24

3

14

22

30

0

0

0

1

5

10

Repayment of convertible debentures

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

51

Net (used in) provided by financing activities

-49

-73

13,668

-674

601

-0

-108

-106

9

118

-8

12,587

0

6,877

-43

-72

0

-34

-71

-69

26,636

-40

-65

16,850

0

185

-1

5,011

72

97

1,706

1,094

98

1,050

0

-1

449

533

Net (decrease) increase in cash and cash equivalents

-1,958

-2,583

-

-

325

-112

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NET CHANGE IN CASH

-

-

-

-

-

-

-684

-779

-3,508

-4,077

-5,278

8,558

-3,967

942

-5,076

-4,257

-3,444

-3,371

-2,282

-1,843

22,382

-2,779

-1,657

11,403

-542

-1,106

-925

4,283

-303

-563

1,187

669

-486

792

-408

-231

317

370

Cash paid for interest

0

1

2

0

0

0

2

4

1

1

3

4

-0

1

-

-

-

0

2

2

1

0

5

0

0

0

1

2

-0

0

0

0

0

0

21

0

0

2

Cash paid for income taxes

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Issuance of common stock for research and development expense-licenses acquired

0

0

-

-

0

844

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrant liability issued for research and development expense- licenses acquired

0

0

-

-

0

104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock and warrants issued in advance of services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Financing of insurance premiums through issuance of short term notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

63

0

0

74

0

0

0

-

-

-

-

Settlement of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,364

0

0

2,061

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of preferred for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

Reclassification of derivative liability to permanent equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,454

0

0

-

-

-

-

Common stock issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

50

0

0

0

50

-

-

-

0

-

-

-

-

-

-

-

-

Noncash exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Transfer of investment for dividends payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Purchase of patents for debenture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Conversion of debenture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Common stock issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Options issued to settle accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

0

0

Stock subscription receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

-

-

-

-